Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease

被引：136
|
作者：
Kappel, Ben A. [1 ]
Lehrke, Michael [1 ]
Schutt, Katharina [1 ]
Artati, Anna [2 ]
Adamski, Jerzy [2 ,3 ,4 ]
Lebherz, Corinna [1 ]
Marx, Nikolaus [1 ]
机构：
[1] Rhein Westfal TH Aachen, Univ Hosp Aachen, Dept Internal Med 1, Pauwelsstr 30, D-52074 Aachen, Germany
[2] German Res Ctr Environm Hlth, Helmholtz Zentrum Muchen, Genome Anal Ctr, Inst Expt Genet, Neuherberg, Germany
[3] Tech Univ Munich, Life & Food Sci Ctr Weihenstephan, Inst Expt Genet, Freising Weihenstephan, Germany
[4] German Ctr Diabet Res, Neuherberg, Germany
来源：
CIRCULATION | 2017年 / 136卷 / 10期
关键词：
branched-chain amino acids; cardiovascular disease; empagliflozin; ketone bodies; metabolomics; SGTL2; inhibitors; type 2 diabetes mellitus; OUTCOMES;
D O I：
10.1161/CIRCULATIONAHA.117.029166
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：969 / 972
页数：4
相关论文
共 50 条
  • [11] Implementation of Empagliflozin in Patients with Diabetes Mellitus Type 2 and Established Cardiovascular Disease: Estimation of 5-Year Survival and Costs in Sweden
    Bernfort, Lars
    Husberg, Magnus
    Wirehn, Ann-Britt
    Rosenqvist, Ulf
    Gustavsson, Staffan
    Karlsdotter, Kristina
    Levin, Lars-Ake
    DIABETES THERAPY, 2020, 11 (12) : 2921 - 2930
  • [12] Cardiovascular Disease in Japanese Patients with Type 2 Diabetes Mellitus
    Fujihara, Kazuya
    Sone, Hirohito
    ANNALS OF VASCULAR DISEASES, 2018, 11 (01) : 2 - 14
  • [13] Prevalence of Established Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in the UK
    Lautsch, Dominik
    Wang, Tongtong
    Yang, Lingfeng
    Rajpathak, Swapnil N.
    DIABETES THERAPY, 2019, 10 (06) : 2131 - 2137
  • [14] Empagliflozin/linagliptin single-pill combination therapy for patients with type 2 diabetes mellitus
    Jain, Rajeev Kumar
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (06) : 545 - 549
  • [15] Type 2 diabetes mellitus and cardiovascular disease: focus on the effect of antihyperglycemic treatments on cardiovascular outcomes
    Choxi, Ravi
    Roy, Sumon
    Stamatouli, Angeliki
    Mayer, Stephanie B.
    Jovin, Ion S.
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2020, 18 (04) : 187 - 199
  • [16] Predictors of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus
    Tan, M. C.
    Wong, T. W.
    Chan, Y. M.
    Joseph, A.
    Hejar, A. R.
    Ng, O. C.
    INTERNATIONAL JOURNAL OF COLLABORATIVE RESEARCH ON INTERNAL MEDICINE & PUBLIC HEALTH, 2013, 5 (07) : 492 - 506
  • [17] Metabolic and renal outcomes of empagliflozin in patients with type 2 diabetes mellitus attending Armed Forces Hospital in Saudi Arabia
    Alshahrani, Ali A.
    Al Qahtani, Saad S.
    Al Qahtani, Abrar S.
    Mashhour, Saeed M.
    Alkhtani, Zayed S.
    Alragea, Yahya M.
    SAUDI MEDICAL JOURNAL, 2023, 44 (07) : 674 - 678
  • [18] Effect of Empagliflozin and Dapagliflozin on Ambulatory Arterial Stiffness in Patients with Type 2 Diabetes Mellitus and Cardiovascular Co-Morbidities: A Prospective, Observational Study
    Patoulias, Dimitrios
    Papadopoulos, Christodoulos
    Zografou, Ioanna
    Katsimardou, Alexandra
    Karagiannis, Asterios
    Doumas, Michael
    MEDICINA-LITHUANIA, 2022, 58 (09):
  • [19] Cardiovascular outcomes between dapagliflozin versus empagliflozin in patients with diabetes mellitus
    Kim, Jee-Heon
    Yoon, Young-Chae
    Kim, Young-Hoon
    Park, Jong-Il
    Choi, Kang-Un
    Nam, Jong-Ho
    Lee, Chan-Hee
    Son, Jang-Won
    Park, Jong-Seon
    Kim, Ung
    CLINICAL CARDIOLOGY, 2024, 47 (03)
  • [20] Usefulness of Empagliflozin Versus Oral Semaglutide for Prevention of Cardiovascular Mortality in Patients With Type 2 Diabetes Mellitus
    Hammerman, Ariel
    Moore, Candace Makeda
    Aboalhasan, Enis
    Azuri, Joseph
    Arbel, Ronen
    AMERICAN JOURNAL OF CARDIOLOGY, 2022, 170 : 128 - 131
12345